Usefulness of S100A12 as a prognostic biomarker for adverse events in patients with heart failure.
Clin Biochem
; 48(4-5): 329-33, 2015 Mar.
Article
em En
| MEDLINE
| ID: mdl-25438075
ABSTRACT
OBJECTIVES:
S100A12 has been proposed as a novel pivotal factor in inflammation produced by granulocytes. The purpose of this study was to investigate the relationship between S100A12 and chronic heart failure (CHF). DESIGN ANDMETHODS:
One hundred and seventy-seven patients with CHF and 66 subjects without CHF were included in this study. Plasma levels of S100A12 and high-sensitivity C-reactive protein (hs-CRP) were measured in all participants. After a follow-up period of 18months for CHF patients, major cardiovascular events (MCE), including cardiac death and rehospitalization for heart failure, were recorded.RESULTS:
Plasma levels of S100A12 were significantly higher in CHF patients than in control subjects (P<0.001) and positively correlated with hs-CRP (r=0.316, P<0.001). S100A12 levels were also higher in MCE patients than in MCE-free patients. The occurrence of MCE increased with advancing plasma S100A12 levels by stratification according to quartiles (Q4 vs Q1, P=0.015). Cox proportional hazards regression analysis revealed that S100A12 was an independent risk factor for MCE in CHF patients (P=0.009).CONCLUSIONS:
S100A12 is a potential biomarker of CHF that may provide important information regarding the prediction of MCE in patients with CHF.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Proteína S100A12
/
Insuficiência Cardíaca
Tipo de estudo:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article